Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The big pharma companies Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,” mitigating a raft of health conditions beyond obesity and diabetes amid increased competition in the weight-loss space. Researchers have now mapped the effectiveness and risks of GLP-1 agonists in the largest study to date of their health impact beyond diabetes and weight-loss.